VivoSeq
Ophthalmology

Retinitis Pigmentosa (RP)

3

Pipeline Programs↗

4

Active Trials↗

1

Companies Involved↗

Retinitis Pigmentosa (RP) is an early-stage landscape with 3 programs across 1 company. The most active players are Nacuity Pharmaceuticals, Inc.. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

N

Nacuity Pharmaceuticals, Inc.

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

3programs
Small molecule133%
Monoclonal antibody133%
RNA therapy133%

Modality classified for 100% of 3 pipeline programs.

Analysis

Trial Status

4

clinical trials

Active, not recruiting2 · 50%
Recruiting1 · 25%
Not yet recruiting1 · 25%

Clinical Trials

Trial Activity

A Two-Year Double-masked, Randomized, Sham-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
Active, not recruiting·LLaboratoires Thea·Phase 2·NCT06627179·81 enrolled
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Evaluate Non-invasive Brain Stimulation Effects on Orientation and Mobility Performance in Adults With Visual Impairments
Recruiting·UUniversity of Waterloo·Preclinical·NCT07341763·20 enrolled
A 24-Month, Randomized, Double-Masked, Placebo-Controlled Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
Not yet recruiting·NNacuity Pharmaceuticals, Inc.·Phase 3·NCT07290530·80 enrolled
Intravitreal Adalimumab in Inherited and Degenerative Retinal Diseases: A Prospective Comparative Pilot Study
Active, not recruiting·CCentro de Pesquisa Rubens Siqueira·Preclinical·NCT07348588·30 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)